Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the rate and/or durability of response to existing cancer therapies. The Company’s small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. The Company uses its deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. The Company has used this platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

Stock Quote: DCPH

Price

$22.96

Change

2.00

High

$23.41

Minimum 15 mins. delay, data provided by Nasdaq

more details

Press Releases

Nov
08
2018
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results
read more

Oct
23
2018
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
read more

Presentations & Events

There are currently no events to display.

Corporate Presentation – November 2018

download

Testing display of HTML elements – h1 tag

This is a test paragraph.

This is 2nd level heading – h2 tag

This is a test paragraph.

This is 3rd level heading – h3 tag

This is a test paragraph.

This is 4th level heading – h4 tag

This is a test paragraph.

This is 5th level heading

This is a test paragraph.

This is 6th level heading

This is a test paragraph.

Basic block level elements

This is the ALT tag for the image
This is the caption for the image

TOGETHER WE… believe that MicroRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.

This is a normal paragraph. To add some length to it, let us mention that this page was primarily written for testing the effect of user style sheets. You can use it for various other purposes as well, like just checking how your browser displays various HTML elements by default. It can also be useful when testing conversions from HTML format to other formats, since some elements can go wrong then. Dysregulated microRNA expression is a key factor in many complex multi-factoral diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. microRNA therapeutics are oligonucleotides that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat a broad range human disease.[blue_band]This is another paragraph. I think it needs to be added that the set of elements tested is not exhaustive in any sense.[/blue_band]

Balboa Park 1915 caption
Balboa Park 1915 caption

microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes and these genes are involved in biological networks or pathways.

this is a blockquote

I have selected those elements for which it can make sense to write user style sheet rules, in my opinion.

Lists

  • One.
  • Two.
  • Three. Well, probably this list item should be longer. Note that for short items lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  • Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.

lorum ipsum text here to show odd

lorem upsum to show even


This is a paragraph before a numbered list (ol). Note that the spacing between a paragraph and a list before or after that is hard to tune in a user style sheet. You can”t guess which paragraphs are logically related to a list, e.g. as a “list header”.

  1. One.
  2. Two.
  3. Three. Well, probably this list item should be longer. Note that if items are short, lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  4. Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.

Links

This is a text paragraph that contains some inline links. Generally, inline links (as opposite to e.g. links lists) are problematic from the usability perspective, but they may have use as “incidental”, less relevant links. See the document Links Want To Be Links.

Buttons

Tables

The following table has a caption. The first column contain table header cells (th elements) only; other cells are data cells with even/odd classes.

Sample table: Areas of the Nordic countries, in sq km
Country Total area Land area
Denmark 43,070 42,370
Finland 337,030 305,470
Iceland 103,000 100,250
Norway 324,220 307,860
Sweden 449,964 410,928